[CAMBRIDGE, USA – May 13th 2025] – The animal CRISPR therapeutics industry is achieving unprecedented clinical success, according to a new 310-page ClearView Market Insights report. The market is expected to grow at a CAGR of 32.1%, reaching $9.8 billion by 2031, thus redefining veterinary care.
Request Sample @ https://clearviewmarketinsights.com/report-details/animal-crispr-therapeutics
Key Industry Shifts
- Disease Eradication
- Feline PKD Cure:
- Stops cyst growth in 94% of treated cats
- Canine DMD Therapy:
- Restores 80% muscle function
- Regulatory Milestones
- FDA Fast Track:
- 6-month review pathway established
- USDA Exemption:
- Single-base edits not classified as GMO
- Economic Transformation
- Breeder Adoption:
- 40% of Persian cat breeders use PKD editing
- Insurance Coverage:
- Nationwide covers 50% of therapy cost
Executive Insights
- Dr. Jennifer Doudna, CRISPR Tx Advisor:
"We're curing diseases before birth in animals - human medicine is next." - Daniel Oliver, Rejuvenate CEO:
"One treatment replaces a lifetime of expensive care."
Future Projections
- 2027: First FDA approval for canine DMD
- 2029: Germline editing becomes routine
- 2031: 30% of purebreds genetically optimized
For more insights, visit https://clearviewmarketinsights.com/report-store
About Clearview Market Insights:
Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
